Related references
Note: Only part of the references are listed.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
Michele Reni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
V. J. Picozzi et al.
ANNALS OF ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study
Jean-Luc Van Laethem et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
Giuseppe Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-α2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC)
A. Marten et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?
Michele Reni
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma:: A dose-finding study
M. Reni et al.
CANCER INVESTIGATION (2007)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
M. Reni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial
Michele Reni et al.
PANCREATOLOGY (2006)
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
H Oettle et al.
ANNALS OF ONCOLOGY (2005)
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
M Reni et al.
LANCET ONCOLOGY (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer
DD Stocken et al.
BRITISH JOURNAL OF CANCER (2005)
Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma
M Reni et al.
ONCOLOGY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Definitive results of a phase II trial of cisplatin epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma
M Reni et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)